CAN14

CAN14 and IL1RAP-based bispecific antibodies

CAN14

The preclinical CAN14 project aims to develop a bispecific IL1RAP antibody which, in addition to blocking signaling from the IL-1 superfamily, adds functionality (undisclosed second target) for further enhanced efficacy.

CAN14 is Cantargia's newest project and, just like CAN10, it is created based on Cantargia's CANxx platform. In addition to CAN14, Cantargia is exploring further possibilities in bispecific anti-IL1RAP antibodies.